Extensive non-small cell lung cancer treated with mitomycin, cisplatin, and vindesine (MiPE): A Southwest Oncology Group Study

T. P. Miller, R. B. Vance, F. R. Ahmann, S. R. Rodney

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

Ninety-seven previously untreated patients with metastatic non-small cell lung cancer were treated with combination chemotherapy consisting of mitomycin (10 mg/m2) on Day 1, cisplatin (50 mg/m2) on Days 1 and 22, and vindesine (3 mg/m2) on Days 1 and 22 (MiPE). MiPE was repeated at 6-week intervals until disease progression or unacceptable toxicity. The overall response rate was 33%. There were seven complete responses (7%) and 25 partial responses (26%). The median progression-free interval for responding patients was 7 months. Median survival for all patients was 5 months, with 16% surviving 1 year. One patient died from sepsis while neutropenic. The results with MiPE treatment for patients with non-small cell lung cancer compare favorably to other mitomycin-vinca combinations previously tested in the Southwest Oncology Group.

Original languageEnglish (US)
Pages (from-to)1101-1104
Number of pages4
JournalCancer Treatment Reports
Volume70
Issue number9
StatePublished - 1986
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Extensive non-small cell lung cancer treated with mitomycin, cisplatin, and vindesine (MiPE): A Southwest Oncology Group Study'. Together they form a unique fingerprint.

Cite this